Pharma Patent-Cliff and Pipeline Replacement Tracker (2026–2030): Drugs, Sales at Risk and the Next Growth Engines
Last updated: October 30, 2026
Pharmaceutical companies face a recurring challenge: blockbuster medicines eventually lose patent protection or other forms of market exclusivity, allowing generic drugs or biosimilars to compete. The resulting price and market-share declines can put billions of dollars in annual sales at risk.
For investors, however, the important question is not simply when does a drug go off patent? It is whether the company has developed, acquired or launched enough new products to replace the revenue that may disappear.
This Pharma Patent-Cliff and Pipeline Replacement Tracker connects four investment questions:
- Which major drugs face generic or biosimilar competition, and when?
- How much annual product revenue is exposed?
- Which approved medicines and pipeline candidates could help replace those sales?
- Is the company demonstrating replacement through actual revenue growth, or relying primarily on future clinical and regulatory milestones?
The analysis focuses on the US market because US patent litigation, regulatory exclusivity and generic or biosimilar launch dates materially affect many pharmaceutical companies. International patent protection can differ substantially.
Important: This is an independent investment-research framework, not legal advice, a prediction of exact generic-launch dates, or a recommendation to buy or sell any security.
Key findings at a glance
- 2026: Several major products are already experiencing generic or biosimilar competition, including Farxiga, Januvia and Pomalyst. The investment question is increasingly the speed of revenue erosion rather than the original patent-expiry date.
- 2027: Ibrance, Xtandi, Trulicity and Lynparza are important names to monitor, although their exact commercial transition dates depend on the relevant patents, settlements and market.
- 2028: Keytruda, Eliquis and Opdivo create an unusually important cluster of potential US exclusivity events. The three products generated approximately $56 billion in combined worldwide sales in 2025, using the figures reported by the referenced patent-cliff tracker.
- 2029–2030: Darzalex, Jardiance, Ocrevus, Cosentyx, Vraylar and Taltz feature in the forward watchlist. Some products have secondary patents or formulations that could extend protection beyond the earliest patent date.
- Replacement matters as much as expiry: AbbVie's transition from Humira toward Skyrizi and Rinvoq provides a useful example of replacement revenue that can be measured in reported financial results rather than inferred solely from a clinical pipeline.
The product-level dates and sales figures below are based principally on the Pharma Patent Cliff tracker, which reports data as of October 24, 2026, and on company filings and results where linked. Sales figures are generally 2025 worldwide product sales, not the amount a company is certain to lose.
How to read this tracker
Patent expiry is not the same as generic launch
A drug can be protected by multiple layers of intellectual property and regulatory exclusivity. These may include:
- Composition-of-matter patents: Protect the active molecule itself.
- Formulation and delivery patents: Protect particular formulations, devices, routes of administration or delivery systems.
- Method-of-use patents: Protect specific approved or claimed therapeutic uses.
- Regulatory exclusivity: Can restrict competing approvals independently of a particular patent.
- Litigation, settlements and launch agreements: Can change when a competing product can legally enter the market.
Small-molecule drugs generally face generic competition through the applicable regulatory pathway. Biologic drugs face biosimilar competition, which involves a different approval process. Neither a listed patent-expiry date nor the filing of a competing application guarantees that a lower-priced competitor will launch immediately.
What does sales at risk mean?
Sales at risk means the existing annual sales associated with a product exposed to potential competition. It does not mean that all those sales will disappear.
Revenue erosion varies with the type of medicine, the number and timing of competitors, pricing, reimbursement, manufacturing capacity, switching behaviour and the strength of the original brand. Some products retain substantial sales after generic entry; others decline rapidly.
How pipeline replacement is assessed
- Demonstrated: Newer approved products are already generating substantial and growing revenue.
- Commercial build-out: Approved products are growing but have not yet demonstrated the scale necessary to replace the exposed franchise.
- Late-stage dependent: The replacement thesis relies materially on regulatory submissions, pivotal trials or unproven launches.
- Early-stage dependent: The company needs future clinical successes, acquisitions or additional growth sources whose commercial contribution remains uncertain.
These are qualitative research categories, not guarantees of future performance or formal investment ratings.
Patent-cliff tracker: 2026
Products already facing competition or an imminent commercial transition
1. Farxiga (dapagliflozin) — AstraZeneca
- 2025 worldwide sales exposure: Approximately $8.4 billion.
- US status: The first US generics were approved on April 6, 2026, according to the current tracker.
- Replacement question: Can growth from AstraZeneca's oncology, biologics and other therapeutic franchises offset pressure on this cardiometabolic medicine?
- What to monitor: US sales trends, generic uptake, international patent status and the contribution of newer approved products.
2. Januvia and Janumet — Merck
- 2025 worldwide sales exposure: Approximately $2.5 billion for the tracked product group.
- US status: Generic entry began in May 2026 under settlements, with additional timing differences among formulations.
- Replacement question: How much incremental revenue can Merck generate from newer medicines and its broader oncology and cardiovascular portfolios?
- What to monitor: Reported sales declines, price concessions and contributions from products such as Winrevair and Welireg.
3. Xolair (omalizumab) — Roche and Novartis
- 2025 worldwide sales exposure: Approximately $5.4 billion using the tracker’s combined estimate.
- US status: The tracker records the launch of Celltrion's Omlyclo as the first US biosimilar on October 5, 2026.
- Replacement question: Can the companies preserve revenue through other immunology products, differentiated formulations and additional indications?
- What to monitor: Actual biosimilar uptake, payer positioning and sales trends across both companies. The two companies' reported figures should not automatically be treated as identical or added without checking geographic and accounting boundaries.
4. Perjeta (pertuzumab) — Roche
- 2025 worldwide sales exposure: Approximately $3.6 billion.
- US status: Roche reported that primary US and European patents expired in the second quarter of 2025, with first biosimilar competition expected in 2026.
- Replacement or defence strategy: Monitor Phesgo, which combines pertuzumab and trastuzumab in a single injection, as well as Roche's broader oncology portfolio.
- What to monitor: Biosimilar launch timing, patient switching and the extent to which combination products preserve the commercial franchise.
5. Pomalyst (pomalidomide) — Bristol Myers Squibb
- 2025 worldwide sales exposure: Approximately $2.7 billion.
- US status: Generic launches were reported in March 2026 under settlements.
- Replacement question: Can the company's growing oncology and cell-therapy portfolio replace the revenue erosion across older cancer medicines?
- What to monitor: Generic erosion alongside growth in Reblozyl, Breyanzi and other newer products.
6. Simponi (golimumab) — Johnson & Johnson
- 2025 worldwide sales exposure: Approximately $2.7 billion.
- US status: The tracker records FDA approval of the first biosimilars in May 2026 and a planned US launch in the fourth quarter of 2026.
- Replacement question: Can newer immunology medicines, including Tremfya, maintain revenue growth as established brands face competition?
- What to monitor: Actual launch dates and sales erosion. Approval and planned launch should be tracked separately.
7. Opsumit (macitentan) — Johnson & Johnson
- 2025 worldwide sales exposure: Approximately $2.3 billion in the tracker.
- US status: The tracker reports generic entry in the second quarter of 2026.
- What to monitor: Sales declines and the performance of the company's wider pulmonary-hypertension portfolio.
Patent-cliff tracker: 2027
8. Xtandi (enzalutamide) — Astellas and Pfizer
- 2025 worldwide sales exposure: Approximately $6.0 billion.
- US risk window: The tracker identifies August 2027 as the expiry of the last listed US patent.
- Replacement question: Can the partners sustain oncology growth through their wider prostate-cancer and precision-oncology portfolios?
- What to monitor: Actual patent challenges, settlement terms, generic-launch timing and each company's separately reported economics.
9. Trulicity (dulaglutide) — Eli Lilly
- 2025 worldwide sales exposure: Approximately $4.3 billion.
- US risk window: Lilly's 2025 filing identifies 2027 as the year in which US compound-patent protection and data protection end.
- Replacement question: Can newer diabetes and obesity products sustain revenue as an established GLP-1 medicine faces competition?
- What to monitor: The rate of Trulicity sales decline, new-product growth and whether growth in newer incretin therapies compensates for lost revenue at the company level.
10. Ibrance (palbociclib) — Pfizer
- 2025 worldwide sales exposure: Approximately $4.1 billion.
- US risk window: Patent term extension reaches March 2027, with pediatric exclusivity extending to September 2027, according to the referenced tracker.
- Replacement question: Can newer oncology products and other growth franchises compensate for a mature breast-cancer blockbuster?
- What to monitor: Competitive pressure in the CDK4/6 inhibitor market, patient share, price erosion and the growth contribution of Pfizer's newer medicines.
11. Trelegy Ellipta — GSK
- 2025 worldwide sales exposure: Approximately $3.9 billion.
- US risk window: The compound patent expires in 2027, while inhaler and formulation patents extend into 2030 and potentially 2031 with pediatric exclusivity.
- Why this matters: A medicine's earliest compound-patent expiry may precede the date when a commercially viable competitor can enter.
- What to monitor: The complete patent estate, device protection, regulatory filings and launch settlements.
12. Lynparza (olaparib) — AstraZeneca and Merck
- 2025 worldwide sales exposure: Approximately $3.3 billion.
- US risk window: The tracker identifies 2027 for the basic US patent, with generic challenges and litigation affecting the timing of entry.
- Replacement question: Can the partners sustain growth through other oncology medicines, combinations and pipeline launches?
- What to monitor: Court outcomes, settlements and each partner's share of product economics. Collaborative products should not be double-counted when assessing corporate exposure.
Patent-cliff tracker: 2028 — the critical watchlist
The 2028 group is especially important because it includes large oncology and cardiovascular franchises. The precise timing and extent of competition will differ by product, but the concentration of sales makes this a major period to monitor.
13. Keytruda (pembrolizumab) — Merck
- 2025 worldwide sales: Approximately $31.7 billion for Keytruda and Keytruda Qlex.
- US risk window: Merck's 2025 Form 10-K identifies December 2028 for the primary US compound patent. The company expects biosimilar competition to materially affect sales between 2028 and 2029, depending on patent litigation and launch timing.
- International distinction: Merck reports European market exclusivity extending to 2031.
- Commercial defence: Keytruda Qlex provides subcutaneous administration and may help defend the franchise. However, a change in formulation or delivery route should not be assumed to remove the risk associated with the underlying compound patent.
- Replacement assets to monitor: Winrevair, Welireg, and Merck's investigational oncology medicines and combinations.
14. Eliquis (apixaban) — Bristol Myers Squibb and Pfizer
- 2025 worldwide sales exposure: Approximately $14.4 billion as reported by Bristol Myers Squibb.
- US risk window: The current tracker reports that US generic entry is barred until April 1, 2028, following patent litigation and settlements.
- International distinction: Generic competition can occur earlier outside the US.
- Replacement question: Can Bristol Myers Squibb's newer portfolio replace the sales of Eliquis alongside losses from other mature products? How material will the impact be to Pfizer's separately reported alliance revenue?
- What to monitor: Actual generic-launch dates, anticoagulant pricing, prescription share and partner-specific revenue exposure.
15. Opdivo (nivolumab) — Bristol Myers Squibb
- 2025 worldwide sales: Approximately $10.0 billion.
- US risk window: Bristol Myers Squibb has guided to US biosimilar entry from 2028, according to the current tracker.
- Commercial defence: Opdivo Qvantig, a subcutaneous formulation, is one product-level strategy to defend the franchise. Its success will depend on uptake, pricing, clinical suitability and the scope of future competition.
- Replacement products to monitor: Reblozyl, Breyanzi, Opdualag, Camzyos and Cobenfy, as well as the company's wider development portfolio.
- What to monitor: Qvantig sales, new indications, patent disputes and the contribution from newer products relative to erosion across the legacy portfolio.
16. Gardasil — Merck
- 2025 worldwide sales exposure: Approximately $5.2 billion.
- US risk window: Key patents are estimated to expire around 2028 in the referenced tracker.
- Additional business risk: Sales also depend on vaccination demand, geographic mix, procurement and public-health policies. Patent expiry is not the only factor that can affect the franchise.
- What to monitor: Patent litigation, regional demand, new vaccine opportunities and the contribution of non-Gardasil growth products.
17. Tecentriq (atezolizumab) — Roche
- 2025 worldwide sales exposure: Approximately $4.3 billion.
- US risk window: The tracker identifies the end of the 12-year US biologic-exclusivity period in May 2028.
- Important qualification: Roche's patent coverage could extend beyond that date. The end of biologic exclusivity is not a confirmed biosimilar-launch date.
- What to monitor: FDA Purple Book information, relevant patents, litigation, biosimilar applications and the ability of Roche's newer medicines to maintain oncology revenue.
18. Jakafi (ruxolitinib) — Incyte
- 2025 worldwide sales: Approximately $3.1 billion, with the company reporting US product revenue as its main commercial concentration.
- US risk window: Incyte's 2025 Form 10-K identifies 2028 as the estimated minimum market-exclusivity date.
- Replacement products: Opzelura, Niktimvo and other marketed medicines are relevant to the broader replacement assessment.
- Risk assessment: High concentration risk. When one medicine represents a substantial share of corporate revenue, its replacement products need to reach meaningful scale rather than simply demonstrate promising growth percentages.
- What to monitor: Jakafi revenue trends, generic timing, Opzelura growth and whether newer medicines generate enough revenue to reduce dependence on the established franchise.
19. Otezla (apremilast) — Amgen
- 2025 worldwide sales exposure: Approximately $2.3 billion.
- US risk window: The referenced tracker identifies August 16, 2028, after pediatric exclusivity, as a key date associated with generic competition.
- What to monitor: Settlement terms, actual launch timing, formulation-specific patents and the contribution of newer Amgen products.
Patent-cliff tracker: 2029
20. Darzalex (daratumumab) — Johnson & Johnson
- 2025 worldwide sales exposure: Approximately $14.3 billion.
- US risk window: Core US patents are expected to expire in 2029 according to the referenced tracker.
- Commercial defence: Darzalex Faspro, a subcutaneous formulation, has formulation patents that may run longer than some core patents.
- Replacement products to monitor: Carvykti, Tremfya and the broader oncology and immunology portfolios.
- What to monitor: Patent litigation, formulation-specific protection, future competition, Carvykti's revenue growth and the performance of other oncology medicines.
21. Jardiance (empagliflozin) — Boehringer Ingelheim and Eli Lilly
- 2025 worldwide sales exposure: Approximately $9.9 billion in the tracker. The companies report revenue through their collaboration, so figures must be reconciled before calculating combined exposure.
- US risk window: Lilly's 2025 filing identifies 2029 for the US compound patent, including pediatric exclusivity; some later use patents extend to 2034.
- What to monitor: Patent challenges, launch agreements, cardiovascular and renal indications, price pressure and the contribution of newer products at both partners.
22. Ocrevus (ocrelizumab) — Roche
- 2025 worldwide sales exposure: Approximately $8.4 billion.
- US risk window: The referenced tracker estimates that main US patent protection runs to March 2029.
- What to monitor: Biosimilar development, patent litigation, the uptake of subcutaneous administration and Roche's broader neuroscience portfolio.
23. Cosentyx (secukinumab) — Novartis
- 2025 worldwide sales exposure: Approximately $6.7 billion.
- US risk window: Key exclusivities are expected to end around 2029, subject to the applicable patent and regulatory details.
- Replacement question: Can Novartis sustain immunology growth from newer medicines while managing potential biosimilar competition?
- What to monitor: Patent disputes, competing products, geographic sales mix and growth from newer immunology and oncology assets.
24. Shingrix — GSK
- 2025 worldwide sales exposure: Approximately $4.8 billion.
- US risk window: The main US patent is listed through 2029 in the referenced tracker.
- What to monitor: Patent status, vaccination demand, market maturity and how GSK's other vaccines and medicines contribute to company-wide growth.
25. Vraylar (cariprazine) — AbbVie
- 2025 worldwide sales exposure: Approximately $3.6 billion.
- US risk window: The compound patent runs to June 2029 with pediatric exclusivity; a second compound and use patent runs to March 2030, according to the tracker.
- Replacement question: Can AbbVie maintain neuroscience growth while also managing its longer-term immunology and oncology portfolio transitions?
- What to monitor: Patent settlements, generic-launch timing and reported revenue contributions from newer neuroscience medicines.
26. Repatha (evolocumab) — Amgen
- 2025 worldwide sales exposure: Approximately $3.0 billion in the referenced tracker.
- US risk window: The US antibody patent expires August 27, 2029, while a method-of-treatment patent extends to May 2032, according to Amgen's filing as cited by the tracker.
- What to monitor: Patent disputes, actual generic or biosimilar launch prospects, cardiovascular outcomes and new indications.
27. Nucala (mepolizumab) — GSK
- 2025 worldwide sales exposure: Approximately $2.6 billion.
- US risk window: The tracker identifies a 2029 latest US molecule-patent date, while other patents extend further.
- What to monitor: Patent and biologic-exclusivity distinctions, biosimilar development, launches and competition within respiratory and immunology medicines.
28. Enbrel (etanercept) — Amgen and Pfizer
- 2025 worldwide sales exposure: Approximately $2.2 billion in the referenced tracker.
- US risk window: Court-upheld patents are reported to block US biosimilar entry until April 2029.
- What to monitor: Litigation, launch settlements, international competition and the performance of each company's newer immunology portfolio.
Patent-cliff tracker: 2030
29. Taltz (ixekizumab) — Eli Lilly
- 2025 worldwide sales exposure: Approximately $3.6 billion.
- US risk window: Lilly's 2025 filing identifies 2030 for the US compound patent, with US biologics data protection running to 2028.
- What to monitor: The later patent position, potential biosimilar development, payer access and replacement growth from Lilly's other immunology and cardiometabolic products.
Cross-year watch: Trelegy's inhaler and formulation patents extend into 2030–2031, while Vraylar has a further listed patent running into March 2030. For products with multiple patent layers, the tracker should retain each relevant date instead of assigning a single, definitive launch date.
Pipeline replacement dashboard: who is actually replacing revenue?
A patent-cliff calendar identifies the problem. The replacement dashboard determines whether the business has a credible response.
Merck: Keytruda creates a high-priority replacement challenge
Exposure: Keytruda and Keytruda Qlex generated approximately $31.7 billion in 2025 worldwide sales. That scale means even a partial erosion can be financially significant.
Approved growth products: Merck reported approximately $1.44 billion in 2025 Winrevair sales. Welireg and other approved medicines add diversification, although each has its own competitive and commercial risks.
Pipeline and lifecycle strategies: Keytruda Qlex provides a subcutaneous delivery option. Merck is also developing additional oncology assets and combinations, including the investigational mRNA cancer therapy V940 in collaboration with Moderna.
Assessment: Commercial build-out, with high reliance on the successful expansion of the broader portfolio. Winrevair's 2025 sales are meaningful, but they are not equivalent to replacing Keytruda's revenue. The portfolio needs to be assessed by actual sales, growth, margins and the timing of future launches.
Bristol Myers Squibb and Pfizer: multiple products, multiple loss-of-exclusivity events
Exposure: Bristol Myers Squibb reported $14.44 billion in 2025 worldwide Eliquis sales and approximately $10.05 billion for Opdivo.
Replacement portfolio: Bristol Myers Squibb reported $26.4 billion in 2025 Growth Portfolio revenue, up 17%. Notable contributors included:
- Reblozyl: approximately $2.33 billion.
- Breyanzi: approximately $1.36 billion.
- Opdualag: approximately $1.19 billion.
- Camzyos: approximately $1.07 billion.
- Cobenfy: approximately $155 million.
Assessment: Bristol Myers Squibb has an established portfolio of growth medicines, but the existence of that portfolio does not guarantee that growth will offset all future legacy-product erosion. Opdivo Qvantig is a lifecycle strategy worth monitoring separately from the underlying Opdivo franchise.
Pfizer should be assessed separately for its share of Eliquis economics and its exposure to Ibrance and Xtandi. Shared products must not be counted as though each partner receives the entire combined worldwide product revenue.
Source: Bristol Myers Squibb FY2025 results
Incyte: Jakafi concentration requires a scale test
Exposure: Incyte reported approximately $3.09 billion in 2025 Jakafi product revenue. The product represents a major part of the company's revenue base.
Replacement candidates: Opzelura generated approximately $678 million in 2025 product revenue, while Niktimvo and other products add further diversification.
Assessment: The important question is whether newer products can grow sufficiently to offset a potential decline in Jakafi. A product growing rapidly from a small base may still contribute too little to replace a mature multi-billion-dollar franchise.
Johnson & Johnson: defend established franchises while scaling new oncology medicines
Exposure: Darzalex is a major product to monitor for the 2029 patent window. The potential effect must be assessed alongside the company's broader portfolio and the protection available to specific formulations.
Replacement candidates: Carvykti generated approximately $1.89 billion in 2025 worldwide sales, with substantial reported growth. Tremfya and other newer medicines are also relevant to the broader commercial picture.
Assessment: J&J has demonstrated growth from newer products, but replacement capacity must be compared with the amount of revenue exposed, the timing of potential erosion and the company's own future patent calendar.
Source: Johnson & Johnson FY2025 results
AbbVie: Humira provides a real-world replacement benchmark
AbbVie's Humira transition is an important case study because it allows investors to examine actual replacement revenue rather than relying solely on forecasts of clinical-trial success.
In 2025, AbbVie reported:
- Skyrizi: approximately $17.56 billion in worldwide revenue.
- Rinvoq: approximately $8.30 billion in worldwide revenue.
- Humira: approximately $4.54 billion in worldwide revenue, following biosimilar competition.
These figures illustrate how an established franchise can be replaced by newer medicines over time. They do not prove that every future loss-of-exclusivity event will be managed equally well: Skyrizi and Rinvoq must also be tracked for patent protection, competitive positioning and their own future revenue risks.
Assessment: Demonstrated replacement revenue. The key ongoing question is whether the newer franchises can maintain growth and support the company through its next patent cycle.
Novo Nordisk: separate regional semaglutide patent dates
Novo Nordisk is a useful example of why a global patent tracker cannot rely on one expiry year for every market.
Novo Nordisk's 2025 annual report identifies US compound-patent expiry for its semaglutide-branded products, including Ozempic and Wegovy, in 2032. The same report lists different dates for China, Japan and Europe. Its patent-status disclosures also distinguish active-ingredient patents from formulation, manufacturing and use patents.
The US position should therefore not be confused with the timing of generic entry in other countries. The tracker should record patent status and commercial entry market by market.
Replacement pipeline to monitor: CagriSema, oral semaglutide products and other next-generation obesity and diabetes medicines should be assessed by their actual regulatory status, clinical evidence, commercial launch and sales contribution.
Assessment: Regional patent risk, with a separate next-generation-product pipeline. Each geography requires its own patent and launch record.
Source: Novo Nordisk 2025 Annual Report
The OneDayAdvisor replacement-coverage score
A useful tracker should answer a more important question than whether a company has a long list of pipeline candidates. It should measure how credible the replacement strategy is relative to the revenue at risk.
OneDayAdvisor can assess each company across five dimensions:
- 1. Size of exposure: What share of the company's revenue comes from products facing potential loss of exclusivity?
- 2. Commercial readiness: How much replacement revenue is already being generated by approved products?
- 3. Pipeline maturity: Are candidate products in early discovery, Phase 1, Phase 2, Phase 3, submitted for approval or already approved?
- 4. Timing: Are replacement products likely to launch before, near or well after the main patent-risk window? A projected launch is not a confirmed launch.
- 5. Execution capacity: Does the company have the manufacturing, regulatory, commercial and financial capacity to develop and launch its replacement products?
Suggested replacement-coverage categories
- Strong demonstrated coverage: Existing approved products already generate substantial revenue, and reported growth offsets a meaningful portion of mature-product erosion.
- Developing coverage: Several approved products are growing, but replacement revenue is not yet sufficient to establish that the upcoming loss will be fully offset.
- Pipeline-dependent: A substantial part of the replacement thesis relies on future regulatory decisions or clinical-trial success.
- High concentration risk: One or two products contribute a large percentage of revenue, with insufficient demonstrated replacement scale.
- Unresolved: Patent timing, market access, product launch or replacement assumptions remain too uncertain for a confident assessment.
These categories should be supported by reported data and explicit assumptions. They should not be translated into a precise probability of clinical or commercial success without a defensible model.
Recommended database structure for a living tracker
For a genuinely useful Pharma Patent-Cliff and Pipeline Replacement Tracker, each drug should have its own record. The same company can have multiple drugs, different patent dates across countries and several replacement candidates at different development stages.
Drug and patent fields
- Company and ticker.
- Brand name and generic name.
- Therapeutic area and mechanism of action.
- Latest reported annual sales and reporting currency.
- US compound-patent expiry.
- US formulation, device and method-of-use patent dates.
- Regulatory exclusivity end date, where applicable.
- Important international expiry dates.
- Generic or biosimilar application, approval and launch status.
- Litigation, settlements and relevant court decisions.
- Primary source, source date and confidence grade.
Replacement-product fields
- Replacement product or pipeline candidate.
- Target indication and whether it overlaps with the exposed franchise.
- Development stage and latest verified milestone.
- Relevant clinical endpoint and trial identifier, where available.
- Regulatory submission, approval and launch dates.
- Latest reported sales, growth rate and contribution to corporate revenue.
- Commercial risks, safety or efficacy uncertainties and competitive alternatives.
- Expected role in replacing revenue: direct franchise defence, new indication, adjacent product, acquisition or diversification.
Financial-analysis fields
- Reported revenue exposed by product and geography.
- Share of company revenue represented by the exposed products.
- Existing replacement revenue from launched products.
- Pipeline revenue assumptions and scenario ranges.
- Estimated timing of erosion under alternative generic-launch scenarios.
- Potential offset from product growth, acquisitions or cost reductions.
- Valuation sensitivity to changes in the replacement scenario.
- Last-reviewed date and the next event that could change the assessment.
The model should distinguish observed financial results from hypothetical scenarios. It should also avoid adding partner revenue twice, treating worldwide product revenue as equivalent to a single company's attributable revenue, or assigning full commercial value to an investigational pipeline candidate.
Tracker update rules
A patent-cliff tracker becomes materially more useful when readers can see what changed and why.
- Quarterly: Refresh product sales, revenue growth, company guidance, replacement-product performance and major pipeline milestones.
- When a patent ruling or settlement occurs: Reassess the earliest plausible generic or biosimilar launch date and distinguish it from the underlying patent expiry date.
- When a competitor is approved: Record approval separately from the actual launch and the first observable sales impact.
- When a clinical trial fails: Reduce reliance on the affected asset in the replacement assessment and reassess the remaining portfolio.
- When a new product launches: Track actual uptake and reported revenue instead of assuming that approval immediately creates meaningful replacement sales.
- When company guidance changes: Record the previous assumption, new guidance, source and date so that readers can see why the assessment changed.
A dated change log would also make this page useful for AI-powered search and financial research: readers could distinguish the latest verified facts from earlier estimates, company forecasts and unresolved uncertainty.
What the tracker means for pharmaceutical investors
The patent cliff should be viewed as a product-level cash-flow and competitive-transition problem rather than an automatic signal to sell a pharmaceutical stock.
Three considerations matter most.
First, the size of the exposed franchise
A company with one dominant blockbuster and limited growth elsewhere can face much greater earnings uncertainty than a diversified company with several commercially established products. Absolute worldwide sales figures are useful for prioritisation, but investors should also calculate exposure as a proportion of company revenue and profit.
Second, the quality of the replacement engine
A large late-stage pipeline is not equivalent to a large commercial business. Approved medicines with growing sales provide stronger evidence of replacement capacity than preclinical projects or early-stage trials. Even Phase 3 candidates can fail, face delayed approvals or launch into more competitive markets than expected.
Third, valuation must reflect the transition
The market may already account for a substantial part of a known patent cliff. Conversely, a high-growth company may be priced as though its replacement pipeline will be unusually successful.
Investors should compare the share price and business valuation with realistic scenarios for revenue erosion, new-product growth, margins, research and development spending, acquisitions and cash flow. A low valuation multiple does not automatically mean a stock is cheap if the earnings base is about to contract.
For related equity research, see the OneDayAdvisor stock research guide.
Limitations and research standards
This tracker is a prioritised watchlist, not an exhaustive global register of every pharmaceutical patent.
- Patent dates and regulatory exclusivity differ by jurisdiction and formulation.
- Sales figures are historical and do not directly estimate future lost revenue.
- Patent disputes, settlements, appeals, manufacturing capacity and launch decisions can change the commercial timeline.
- Company pipeline descriptions are not independent confirmation of future commercial success.
- New-product sales may cannibalise existing products or require substantial additional investment.
- Partnered products may have shared economics; avoid double-counting sales across company-level assessments.
- Government pricing policies, payer negotiations, competition and changes in clinical practice can affect a product independently of its patent position.
Before publishing a definitive expiry date or making a significant investment assessment, verify the relevant company filing, official patent records, regulatory database and any material court ruling or settlement. Where the date is only an industry estimate, label it as such.
Frequently asked questions
What is a pharmaceutical patent cliff?
A pharmaceutical patent cliff is the commercial risk that follows the loss of patent protection or other market exclusivity for a medicine. Competitors may enter with lower-priced generic or biosimilar products, potentially reducing the original manufacturer's market share, sales and profit.
Which pharmaceutical patent cliffs matter most in 2028?
Keytruda, Eliquis and Opdivo are among the most important products to monitor because of their large 2025 worldwide sales and expected US competition windows. Exact entry dates and sales impacts remain dependent on applicable patents, regulatory pathways, litigation and commercial execution.
Does patent expiry mean a generic drug will launch immediately?
No. Regulatory approval, additional patents, exclusivity periods, litigation and launch settlements can all affect the timing. A tracker should record patent expiry, competitor approval and actual commercial launch as separate events.
How can investors tell whether a pharmaceutical company can replace lost sales?
Examine sales from existing growth products, revenue concentration, pipeline maturity, regulatory timing, clinical evidence, pricing, launch capacity and the size of the exposed franchise. Replacement revenue already visible in financial results is stronger evidence than a list of investigational drugs alone.
Why is AbbVie a useful patent-cliff case study?
AbbVie has reported substantial revenue from Skyrizi and Rinvoq while Humira sales have declined following biosimilar entry. This provides a real-world example of how investors can measure a replacement strategy through reported product revenue rather than relying entirely on future forecasts.
Are patent-cliff estimates the same as forecast revenue losses?
No. Sales exposed to potential competition are not equivalent to sales certain to disappear. The eventual effect depends on the number and timing of competitors, pricing, market share, remaining patents, product differentiation and the manufacturer's replacement strategy.
Sources and further reading
- Pharma Patent Cliff — product-level US exclusivity tracker. Includes estimated sales exposed, dates, source references and notes on generic or biosimilar competition.
- BioPharma Dive — Pharma's $500 billion patent problem will come in waves. Published October 12, 2026.
- Merck 2025 Form 10-K.
- Bristol Myers Squibb fourth-quarter and full-year 2025 results.
- Incyte 2025 Form 10-K.
- Johnson & Johnson fourth-quarter and full-year 2025 results.
- AbbVie fourth-quarter and full-year 2025 results.
- Novo Nordisk 2025 Annual Report — patent status by product and geography.
- Eli Lilly 2025 Form 10-K.
- Pfizer fourth-quarter and full-year 2025 results.
Editorial policy: This page is prepared for independent investment education. Patent estimates, company forecasts, sales figures and pipeline claims should be attributed to their sources and updated when material new evidence becomes available. Inclusion of a company or drug does not imply an investment recommendation.
Comments